APO Research
Talk to an analyst

APO RESEARCH · REPORT

Melanoma Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Melanoma Drugs Market Analysis and Forecast 2026-2032

19 December 2025203 pages

Choose your research edition.

Industry ResearchMelanoma Drugs Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Melanoma Drugs Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Melanoma Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Melanoma Drugs Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Melanoma Drugs Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global Melanoma Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Melanoma Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Melanoma Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Melanoma Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Melanoma Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Melanoma Drugs include Grand Pharmaceutical (China) Co., Ltd, Innovent Biologics, Sanofi, Novartis, Merck Group, Roche, Shanghai Junshi Biosciences Co.,Ltd, Pfizer and Jiangsu Hengrui Medicine Co.,Ltd., etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Melanoma Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Melanoma Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Melanoma Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Melanoma Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Melanoma Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Melanoma Drugs revenue, projected growth trends, production technology, application and end-user industry.

Melanoma Drugs Segment by Company

Grand Pharmaceutical (China) Co., Ltd

Innovent Biologics

Sanofi

Novartis

Merck Group

Roche

Shanghai Junshi Biosciences Co.,Ltd

Pfizer

Jiangsu Hengrui Medicine Co.,Ltd.

Bristol-Myers Squibb

BeiGene, Ltd.

Amgen

Teva Pharma

Takeda Pharma

Janssen Biotech

Genentech

Melanoma Drugs Segment by Type

Immunotherapy

Chemotherapy

Targeted Therapy

Melanoma Drugs Segment by Application

Hospitals

Clinics

Others

Melanoma Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Melanoma Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Melanoma Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Melanoma Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Melanoma Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Melanoma Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Melanoma Drugs revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Melanoma Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Immunotherapy Major Player Table 3. Chemotherapy Major Player Table 4. Targeted Therapy Major Player Table 5. Global Melanoma Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospitals Major Player Table 7. Clinics Major Player Table 8. Others Major Player Table 9. Melanoma Drugs Industry Trends Table 10. Melanoma Drugs Industry Drivers Table 11. Melanoma Drugs Industry Opportunities and Challenges Table 12. Melanoma Drugs Industry Restraints Table 13. Global Melanoma Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Melanoma Drugs Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Melanoma Drugs Market Share by Region (2021-2026) Table 16. Global Melanoma Drugs Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Melanoma Drugs Market Share by Region (2027-2032) Table 18. Global Melanoma Drugs Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Melanoma Drugs Revenue Market Share by Players (2021-2026) Table 20. Global Melanoma Drugs Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Melanoma Drugs Key Players Headquarters & Area Served Table 22. Global Melanoma Drugs Players, Product Type & Application Table 23. Global Melanoma Drugs Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Melanoma Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Melanoma Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Melanoma Drugs Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Melanoma Drugs Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Melanoma Drugs Revenue Market Share by Type (2021-2026) Table 30. Global Melanoma Drugs Revenue Market Share by Type (2027-2032) Table 31. Global Melanoma Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Melanoma Drugs Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Melanoma Drugs Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Melanoma Drugs Revenue Market Share by Application (2021-2026) Table 35. Global Melanoma Drugs Revenue Market Share by Application (2027-2032) Table 36. Grand Pharmaceutical (China) Co., Ltd Company Information Table 37. Grand Pharmaceutical (China) Co., Ltd Business Overview Table 38. Grand Pharmaceutical (China) Co., Ltd Melanoma Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Grand Pharmaceutical (China) Co., Ltd Melanoma Drugs Product Portfolio Table 40. Grand Pharmaceutical (China) Co., Ltd Recent Development Table 41. Innovent Biologics Company Information Table 42. Innovent Biologics Business Overview Table 43. Innovent Biologics Melanoma Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Innovent Biologics Melanoma Drugs Product Portfolio Table 45. Innovent Biologics Recent Development Table 46. Sanofi Company Information Table 47. Sanofi Business Overview Table 48. Sanofi Melanoma Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Sanofi Melanoma Drugs Product Portfolio Table 50. Sanofi Recent Development Table 51. Novartis Company Information Table 52. Novartis Business Overview Table 53. Novartis Melanoma Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Novartis Melanoma Drugs Product Portfolio Table 55. Novartis Recent Development Table 56. Merck Group Company Information Table 57. Merck Group Business Overview Table 58. Merck Group Melanoma Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Merck Group Melanoma Drugs Product Portfolio Table 60. Merck Group Recent Development Table 61. Roche Company Information Table 62. Roche Business Overview Table 63. Roche Melanoma Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Roche Melanoma Drugs Product Portfolio Table 65. Roche Recent Development Table 66. Shanghai Junshi Biosciences Co.,Ltd Company Information Table 67. Shanghai Junshi Biosciences Co.,Ltd Business Overview Table 68. Shanghai Junshi Biosciences Co.,Ltd Melanoma Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Shanghai Junshi Biosciences Co.,Ltd Melanoma Drugs Product Portfolio Table 70. Shanghai Junshi Biosciences Co.,Ltd Recent Development Table 71. Pfizer Company Information Table 72. Pfizer Business Overview Table 73. Pfizer Melanoma Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Pfizer Melanoma Drugs Product Portfolio Table 75. Pfizer Recent Development Table 76. Jiangsu Hengrui Medicine Co.,Ltd. Company Information Table 77. Jiangsu Hengrui Medicine Co.,Ltd. Business Overview Table 78. Jiangsu Hengrui Medicine Co.,Ltd. Melanoma Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Jiangsu Hengrui Medicine Co.,Ltd. Melanoma Drugs Product Portfolio Table 80. Jiangsu Hengrui Medicine Co.,Ltd. Recent Development Table 81. Bristol-Myers Squibb Company Information Table 82. Bristol-Myers Squibb Business Overview Table 83. Bristol-Myers Squibb Melanoma Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Bristol-Myers Squibb Melanoma Drugs Product Portfolio Table 85. Bristol-Myers Squibb Recent Development Table 86. BeiGene, Ltd. Company Information Table 87. BeiGene, Ltd. Business Overview Table 88. BeiGene, Ltd. Melanoma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. BeiGene, Ltd. Melanoma Drugs Product Portfolio Table 90. BeiGene, Ltd. Recent Development Table 91. Amgen Company Information Table 92. Amgen Business Overview Table 93. Amgen Melanoma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Amgen Melanoma Drugs Product Portfolio Table 95. Amgen Recent Development Table 96. Teva Pharma Company Information Table 97. Teva Pharma Business Overview Table 98. Teva Pharma Melanoma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Teva Pharma Melanoma Drugs Product Portfolio Table 100. Teva Pharma Recent Development Table 101. Takeda Pharma Company Information Table 102. Takeda Pharma Business Overview Table 103. Takeda Pharma Melanoma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Takeda Pharma Melanoma Drugs Product Portfolio Table 105. Takeda Pharma Recent Development Table 106. Janssen Biotech Company Information Table 107. Janssen Biotech Business Overview Table 108. Janssen Biotech Melanoma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Janssen Biotech Melanoma Drugs Product Portfolio Table 110. Janssen Biotech Recent Development Table 111. Genentech Company Information Table 112. Genentech Business Overview Table 113. Genentech Melanoma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Genentech Melanoma Drugs Product Portfolio Table 115. Genentech Recent Development Table 116. North America Melanoma Drugs Revenue by Type (2021-2026) & (US$ Million) Table 117. North America Melanoma Drugs Revenue by Type (2027-2032) & (US$ Million) Table 118. North America Melanoma Drugs Revenue by Application (2021-2026) & (US$ Million) Table 119. North America Melanoma Drugs Revenue by Application (2027-2032) & (US$ Million) Table 120. North America Melanoma Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 121. North America Melanoma Drugs Revenue by Country (2021-2026) & (US$ Million) Table 122. North America Melanoma Drugs Revenue by Country (US$ Million) & (2027-2032) Table 123. Europe Melanoma Drugs Revenue by Type (2021-2026) & (US$ Million) Table 124. Europe Melanoma Drugs Revenue by Type (2027-2032) & (US$ Million) Table 125. Europe Melanoma Drugs Revenue by Application (2021-2026) & (US$ Million) Table 126. Europe Melanoma Drugs Revenue by Application (2027-2032) & (US$ Million) Table 127. Europe Melanoma Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 128. Europe Melanoma Drugs Revenue by Country (2021-2026) & (US$ Million) Table 129. Europe Melanoma Drugs Revenue by Country (US$ Million) & (2027-2032) Table 130. China Melanoma Drugs Revenue by Type (2021-2026) & (US$ Million) Table 131. China Melanoma Drugs Revenue by Type (2027-2032) & (US$ Million) Table 132. China Melanoma Drugs Revenue by Application (2021-2026) & (US$ Million) Table 133. China Melanoma Drugs Revenue by Application (2027-2032) & (US$ Million) Table 134. Asia Melanoma Drugs Revenue by Type (2021-2026) & (US$ Million) Table 135. Asia Melanoma Drugs Revenue by Type (2027-2032) & (US$ Million) Table 136. Asia Melanoma Drugs Revenue by Application (2021-2026) & (US$ Million) Table 137. Asia Melanoma Drugs Revenue by Application (2027-2032) & (US$ Million) Table 138. Asia Melanoma Drugs Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 139. Asia Melanoma Drugs Revenue by Region (US$ Million) & (2021-2026) Table 140. Asia Melanoma Drugs Revenue by Region (US$ Million) & (2027-2032) Table 141. SAMEA Melanoma Drugs Revenue by Type (2021-2026) & (US$ Million) Table 142. SAMEA Melanoma Drugs Revenue by Type (2027-2032) & (US$ Million) Table 143. SAMEA Melanoma Drugs Revenue by Application (2021-2026) & (US$ Million) Table 144. SAMEA Melanoma Drugs Revenue by Application (2027-2032) & (US$ Million) Table 145. SAMEA Melanoma Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 146. SAMEA Melanoma Drugs Revenue by Country (2021-2026) & (US$ Million) Table 147. SAMEA Melanoma Drugs Revenue by Country (US$ Million) & (2027-2032) Table 148. Research Programs/Design for This Report Table 149. Authors List of This Report Table 150. Secondary Sources Table 151. Primary Sources List of Figures Figure 1. Melanoma Drugs Image Figure 2. Global Melanoma Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Melanoma Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Immunotherapy Image Figure 5. Chemotherapy Image Figure 6. Targeted Therapy Image Figure 7. Global Melanoma Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Melanoma Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospitals Image Figure 10. Clinics Image Figure 11. Others Image Figure 12. Global Melanoma Drugs Market Size (US$ Million) & (2021-2032) Figure 13. Global Melanoma Drugs Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Melanoma Drugs Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Melanoma Drugs Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Melanoma Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Melanoma Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Melanoma Drugs Revenue Market Share by Type (2021-2032) Figure 20. Global Melanoma Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Melanoma Drugs Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Melanoma Drugs Revenue Market Share by Application (2021-2032) Figure 23. North America Melanoma Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Melanoma Drugs Revenue Share by Type (2021-2032) Figure 25. North America Melanoma Drugs Revenue Share by Application (2021-2032) Figure 26. North America Melanoma Drugs Revenue Share by Country (2021-2032) Figure 27. United States Melanoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Melanoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Melanoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Melanoma Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Melanoma Drugs Revenue Share by Type (2021-2032) Figure 32. Europe Melanoma Drugs Revenue Share by Application (2021-2032) Figure 33. Europe Melanoma Drugs Revenue Share by Country (2021-2032) Figure 34. Germany Melanoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Melanoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Melanoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Melanoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Melanoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Melanoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Melanoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Melanoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Melanoma Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Melanoma Drugs Revenue Share by Type (2021-2032) Figure 44. China Melanoma Drugs Revenue Share by Application (2021-2032) Figure 45. Asia Melanoma Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Melanoma Drugs Revenue Share by Type (2021-2032) Figure 47. Asia Melanoma Drugs Revenue Share by Application (2021-2032) Figure 48. Asia Melanoma Drugs Revenue Share by Region (2021-2032) Figure 49. Japan Melanoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Melanoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Melanoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Melanoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Melanoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Melanoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Melanoma Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Melanoma Drugs Revenue Share by Type (2021-2032) Figure 57. SAMEA Melanoma Drugs Revenue Share by Application (2021-2032) Figure 58. SAMEA Melanoma Drugs Revenue Share by Country (2021-2032) Figure 59. Brazil Melanoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Melanoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Melanoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Melanoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Melanoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Melanoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Melanoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Melanoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Melanoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Melanoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Melanoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Immunotherapy
  • Chemotherapy
  • Targeted Therapy
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Grand Pharmaceutical (China) Co., Ltd
  • Innovent Biologics
  • Sanofi
  • Novartis
  • Merck Group
  • Roche
  • Shanghai Junshi Biosciences Co.,Ltd
  • Pfizer
  • Jiangsu Hengrui Medicine Co.,Ltd.
  • Bristol-Myers Squibb
  • BeiGene, Ltd.
  • Amgen
  • Teva Pharma
  • Takeda Pharma
  • Janssen Biotech
  • Genentech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Melanoma Drugs Market by Type
  3. 1.2.1 Global Melanoma Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Immunotherapy
  5. 1.2.3 Chemotherapy
  6. 1.2.4 Targeted Therapy
  7. 1.3 Melanoma Drugs Market by Application
  8. 1.3.1 Global Melanoma Drugs Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospitals
  10. 1.3.3 Clinics
  11. 1.3.4 Others
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Melanoma Drugs Market Dynamics
  1. 2.1 Melanoma Drugs Industry Trends
  2. 2.2 Melanoma Drugs Industry Drivers
  3. 2.3 Melanoma Drugs Industry Opportunities and Challenges
  4. 2.4 Melanoma Drugs Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Melanoma Drugs Market Perspective (2021-2032)
  2. 3.2 Global Melanoma Drugs Growth Trends by Region
  3. 3.2.1 Global Melanoma Drugs Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Melanoma Drugs Market Size by Region (2021-2026)
  5. 3.2.3 Global Melanoma Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Melanoma Drugs Revenue by Players
  2. 4.1.1 Global Melanoma Drugs Revenue by Players (2021-2026)
  3. 4.1.2 Global Melanoma Drugs Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Melanoma Drugs Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Melanoma Drugs Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Melanoma Drugs Key Players Headquarters & Area Served
  7. 4.4 Global Melanoma Drugs Players, Product Type & Application
  8. 4.5 Global Melanoma Drugs Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Melanoma Drugs Market CR5 and HHI
  11. 4.6.3 2025 Melanoma Drugs Tier 1, Tier 2, and Tier 3
5 Melanoma Drugs Market Size by Type
  1. 5.1 Global Melanoma Drugs Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Melanoma Drugs Revenue by Type (2021-2032)
  3. 5.3 Global Melanoma Drugs Revenue Market Share by Type (2021-2032)
6 Melanoma Drugs Market Size by Application
  1. 6.1 Global Melanoma Drugs Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Melanoma Drugs Revenue by Application (2021-2032)
  3. 6.3 Global Melanoma Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Grand Pharmaceutical (China) Co., Ltd
  2. 7.1.1 Grand Pharmaceutical (China) Co., Ltd Company Information
  3. 7.1.2 Grand Pharmaceutical (China) Co., Ltd Business Overview
  4. 7.1.3 Grand Pharmaceutical (China) Co., Ltd Melanoma Drugs Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Grand Pharmaceutical (China) Co., Ltd Melanoma Drugs Product Portfolio
  6. 7.1.5 Grand Pharmaceutical (China) Co., Ltd Recent Developments
  7. 7.2 Innovent Biologics
  8. 7.2.1 Innovent Biologics Company Information
  9. 7.2.2 Innovent Biologics Business Overview
  10. 7.2.3 Innovent Biologics Melanoma Drugs Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Innovent Biologics Melanoma Drugs Product Portfolio
  12. 7.2.5 Innovent Biologics Recent Developments
  13. 7.3 Sanofi
  14. 7.3.1 Sanofi Company Information
  15. 7.3.2 Sanofi Business Overview
  16. 7.3.3 Sanofi Melanoma Drugs Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Sanofi Melanoma Drugs Product Portfolio
  18. 7.3.5 Sanofi Recent Developments
  19. 7.4 Novartis
  20. 7.4.1 Novartis Company Information
  21. 7.4.2 Novartis Business Overview
  22. 7.4.3 Novartis Melanoma Drugs Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Novartis Melanoma Drugs Product Portfolio
  24. 7.4.5 Novartis Recent Developments
  25. 7.5 Merck Group
  26. 7.5.1 Merck Group Company Information
  27. 7.5.2 Merck Group Business Overview
  28. 7.5.3 Merck Group Melanoma Drugs Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Merck Group Melanoma Drugs Product Portfolio
  30. 7.5.5 Merck Group Recent Developments
  31. 7.6 Roche
  32. 7.6.1 Roche Company Information
  33. 7.6.2 Roche Business Overview
  34. 7.6.3 Roche Melanoma Drugs Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Roche Melanoma Drugs Product Portfolio
  36. 7.6.5 Roche Recent Developments
  37. 7.7 Shanghai Junshi Biosciences Co.,Ltd
  38. 7.7.1 Shanghai Junshi Biosciences Co.,Ltd Company Information
  39. 7.7.2 Shanghai Junshi Biosciences Co.,Ltd Business Overview
  40. 7.7.3 Shanghai Junshi Biosciences Co.,Ltd Melanoma Drugs Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Shanghai Junshi Biosciences Co.,Ltd Melanoma Drugs Product Portfolio
  42. 7.7.5 Shanghai Junshi Biosciences Co.,Ltd Recent Developments
  43. 7.8 Pfizer
  44. 7.8.1 Pfizer Company Information
  45. 7.8.2 Pfizer Business Overview
  46. 7.8.3 Pfizer Melanoma Drugs Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Pfizer Melanoma Drugs Product Portfolio
  48. 7.8.5 Pfizer Recent Developments
  49. 7.9 Jiangsu Hengrui Medicine Co.,Ltd.
  50. 7.9.1 Jiangsu Hengrui Medicine Co.,Ltd. Company Information
  51. 7.9.2 Jiangsu Hengrui Medicine Co.,Ltd. Business Overview
  52. 7.9.3 Jiangsu Hengrui Medicine Co.,Ltd. Melanoma Drugs Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Jiangsu Hengrui Medicine Co.,Ltd. Melanoma Drugs Product Portfolio
  54. 7.9.5 Jiangsu Hengrui Medicine Co.,Ltd. Recent Developments
  55. 7.10 Bristol-Myers Squibb
  56. 7.10.1 Bristol-Myers Squibb Company Information
  57. 7.10.2 Bristol-Myers Squibb Business Overview
  58. 7.10.3 Bristol-Myers Squibb Melanoma Drugs Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Bristol-Myers Squibb Melanoma Drugs Product Portfolio
  60. 7.10.5 Bristol-Myers Squibb Recent Developments
  61. 7.11 BeiGene, Ltd.
  62. 7.11.1 BeiGene, Ltd. Company Information
  63. 7.11.2 BeiGene, Ltd. Business Overview
  64. 7.11.3 BeiGene, Ltd. Melanoma Drugs Revenue and Gross Margin (2021-2026)
  65. 7.11.4 BeiGene, Ltd. Melanoma Drugs Product Portfolio
  66. 7.11.5 BeiGene, Ltd. Recent Developments
  67. 7.12 Amgen
  68. 7.12.1 Amgen Company Information
  69. 7.12.2 Amgen Business Overview
  70. 7.12.3 Amgen Melanoma Drugs Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Amgen Melanoma Drugs Product Portfolio
  72. 7.12.5 Amgen Recent Developments
  73. 7.13 Teva Pharma
  74. 7.13.1 Teva Pharma Company Information
  75. 7.13.2 Teva Pharma Business Overview
  76. 7.13.3 Teva Pharma Melanoma Drugs Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Teva Pharma Melanoma Drugs Product Portfolio
  78. 7.13.5 Teva Pharma Recent Developments
  79. 7.14 Takeda Pharma
  80. 7.14.1 Takeda Pharma Company Information
  81. 7.14.2 Takeda Pharma Business Overview
  82. 7.14.3 Takeda Pharma Melanoma Drugs Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Takeda Pharma Melanoma Drugs Product Portfolio
  84. 7.14.5 Takeda Pharma Recent Developments
  85. 7.15 Janssen Biotech
  86. 7.15.1 Janssen Biotech Company Information
  87. 7.15.2 Janssen Biotech Business Overview
  88. 7.15.3 Janssen Biotech Melanoma Drugs Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Janssen Biotech Melanoma Drugs Product Portfolio
  90. 7.15.5 Janssen Biotech Recent Developments
  91. 7.16 Genentech
  92. 7.16.1 Genentech Company Information
  93. 7.16.2 Genentech Business Overview
  94. 7.16.3 Genentech Melanoma Drugs Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Genentech Melanoma Drugs Product Portfolio
  96. 7.16.5 Genentech Recent Developments
8 North America
  1. 8.1 North America Melanoma Drugs Revenue (2021-2032)
  2. 8.2 North America Melanoma Drugs Revenue by Type (2021-2032)
  3. 8.2.1 North America Melanoma Drugs Revenue by Type (2021-2026)
  4. 8.2.2 North America Melanoma Drugs Revenue by Type (2027-2032)
  5. 8.3 North America Melanoma Drugs Revenue Share by Type (2021-2032)
  6. 8.4 North America Melanoma Drugs Revenue by Application (2021-2032)
  7. 8.4.1 North America Melanoma Drugs Revenue by Application (2021-2026)
  8. 8.4.2 North America Melanoma Drugs Revenue by Application (2027-2032)
  9. 8.5 North America Melanoma Drugs Revenue Share by Application (2021-2032)
  10. 8.6 North America Melanoma Drugs Revenue by Country
  11. 8.6.1 North America Melanoma Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Melanoma Drugs Revenue by Country (2021-2026)
  13. 8.6.3 North America Melanoma Drugs Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Melanoma Drugs Revenue (2021-2032)
  2. 9.2 Europe Melanoma Drugs Revenue by Type (2021-2032)
  3. 9.2.1 Europe Melanoma Drugs Revenue by Type (2021-2026)
  4. 9.2.2 Europe Melanoma Drugs Revenue by Type (2027-2032)
  5. 9.3 Europe Melanoma Drugs Revenue Share by Type (2021-2032)
  6. 9.4 Europe Melanoma Drugs Revenue by Application (2021-2032)
  7. 9.4.1 Europe Melanoma Drugs Revenue by Application (2021-2026)
  8. 9.4.2 Europe Melanoma Drugs Revenue by Application (2027-2032)
  9. 9.5 Europe Melanoma Drugs Revenue Share by Application (2021-2032)
  10. 9.6 Europe Melanoma Drugs Revenue by Country
  11. 9.6.1 Europe Melanoma Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Melanoma Drugs Revenue by Country (2021-2026)
  13. 9.6.3 Europe Melanoma Drugs Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
  19. 9.6.9 Nordic Countries
10 China
  1. 10.1 China Melanoma Drugs Revenue (2021-2032)
  2. 10.2 China Melanoma Drugs Revenue by Type (2021-2032)
  3. 10.2.1 China Melanoma Drugs Revenue by Type (2021-2026)
  4. 10.2.2 China Melanoma Drugs Revenue by Type (2027-2032)
  5. 10.3 China Melanoma Drugs Revenue Share by Type (2021-2032)
  6. 10.4 China Melanoma Drugs Revenue by Application (2021-2032)
  7. 10.4.1 China Melanoma Drugs Revenue by Application (2021-2026)
  8. 10.4.2 China Melanoma Drugs Revenue by Application (2027-2032)
  9. 10.5 China Melanoma Drugs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Melanoma Drugs Revenue (2021-2032)
  2. 11.2 Asia Melanoma Drugs Revenue by Type (2021-2032)
  3. 11.2.1 Asia Melanoma Drugs Revenue by Type (2021-2026)
  4. 11.2.2 Asia Melanoma Drugs Revenue by Type (2027-2032)
  5. 11.3 Asia Melanoma Drugs Revenue Share by Type (2021-2032)
  6. 11.4 Asia Melanoma Drugs Revenue by Application (2021-2032)
  7. 11.4.1 Asia Melanoma Drugs Revenue by Application (2021-2026)
  8. 11.4.2 Asia Melanoma Drugs Revenue by Application (2027-2032)
  9. 11.5 Asia Melanoma Drugs Revenue Share by Application (2021-2032)
  10. 11.6 Asia Melanoma Drugs Revenue by Country
  11. 11.6.1 Asia Melanoma Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Melanoma Drugs Revenue by Country (2021-2026)
  13. 11.6.3 Asia Melanoma Drugs Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Melanoma Drugs Revenue (2021-2032)
  2. 12.2 SAMEA Melanoma Drugs Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Melanoma Drugs Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Melanoma Drugs Revenue by Type (2027-2032)
  5. 12.3 SAMEA Melanoma Drugs Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Melanoma Drugs Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Melanoma Drugs Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Melanoma Drugs Revenue by Application (2027-2032)
  9. 12.5 SAMEA Melanoma Drugs Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Melanoma Drugs Revenue by Country
  11. 12.6.1 SAMEA Melanoma Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Melanoma Drugs Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Melanoma Drugs Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst